Efficacy News and Research

RSS

Tenofovir gel reduces HIV by 39% in women: CAPRISA 004 study

Researchers who conducted a study testing a vaginal microbicide with an antiretroviral (ARV) drug called tenofovir found its use before and after sex was significantly more protective against HIV infection than a placebo gel among women at high risk of HIV. Results of the study, known as CAPRISA 004, are to be reported at the International AIDS Conference (AIDS 2010) in Vienna and published online by the journal Science.

20 Jul 2010

NanoViricides presents study results of nanoviricides anti-Ebola agents

NanoViricides, Inc. reports that the results of the evaluation of several of its nanoviricides anti-Ebola agents were presented July 17th at the Annual Meeting of the American Society for Virology, July 17-21, at Montana State University, Bozeman, MT. Dr. Corinne Scully delivered the presentation, which was entitled "Polymeric Micelle Nanomaterials as Antiviral Compounds For Ebola Virus Infection."

20 Jul 2010

New report compares efficacy of Plavix, Effient in treating patients with ACS

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of acute coronary syndrome, 56 percent of surveyed interventional cardiologists who prescribe Bristol-Myers Squibb/Sanofi-Aventis' Plavix in high doses, consider it to be comparable in efficacy to Daiichi Sankyo/Eli Lilly's recently-launched Effient.

20 Jul 2010

Bill Gates calls for renewed focus on reducing new HIV infections

Speaking to the 18th International AIDS Conference today, Bill Gates called on all countries to keep up the fight against HIV/AIDS, saying the world has an historic opportunity to "change the face of AIDS." Mr. Gates said current efforts to treat people with HIV are saving millions of lives, and urged a renewed focus on reducing annual new HIV infections up to 90% by 2031, the year that will mark 50 years of the AIDS epidemic.

20 Jul 2010

CytRx updates on progress in clinical development of bafetinib in three oncology indications

CytRx Corporation, a biopharmaceutical company specializing in oncology, announces progress with its clinical program to evaluate the preliminary efficacy and safety of its drug candidate bafetinib in three oncology indications. The Company has enrolled its first patient in a Phase 2 proof-of-concept trial in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL), is reporting rapid advancement toward the initiation of a Phase 2 proof-of-concept trial in advanced prostate cancer, and is on track to begin clinical evaluation later this year in glioblastoma multiforme, a common and aggressive type of primary brain tumor.

20 Jul 2010

Vertos Medical announces 12-week data from MiDAS I clinical study for lumbar spinal stenosis

Medical device company Vertos Medical Inc. has announced the unveiling of 12-week clinical data from its prospective, 75-patient MiDAS I (mild Decompression Alternative to open Surgery) study that further validate the safety and efficacy of mild for the treatment of lumbar spinal stenosis (LSS). Consistent with the positive six-week study results released in March and May, the new MiDAS I data demonstrate that mild patients continued to experience statistically significant improvement in pain, physical function and mobility 12 weeks following treatment.

20 Jul 2010

ZIOPHARM Oncology commences palifosfamide Phase III clinical trial for metastatic soft tissue sarcoma

ZIOPHARM Oncology, Inc. today announced the initiation of the pivotal Phase III clinical trial for palifosfamide in patients with front-line metastatic soft tissue sarcoma. The study, called PICASSO 3, is an international, randomized, double-blinded, placebo-controlled trial designed to enroll approximately 424 patients with metastatic soft tissue sarcoma who have never been treated with chemotherapy for metastatic disease.

20 Jul 2010

T-SPOT.TB test predicts TB infected persons better than TST: Study

The authors of a recent study published in the American Journal of Respiratory and Critical Care Medicine concluded that the T-SPOT.TB test is better than the tuberculin skin test at predicting which patients will develop active TB.

20 Jul 2010

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

Abbott today presented 48-week findings comparing an HIV regimen of its protease inhibitor (PI), Kaletra® (lopinavir/ritonavir), and Merck's integrase inhibitor, Isentress® (raltegravir), to a traditional HIV regimen of Kaletra and the nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs) in Truvada® (tenofovir and emtricitabine) in antiretroviral-naive adult patients. Efficacy data were collected over the first 48 weeks of the 96-week PROGRESS (PROtease/InteGRasE Simplification Study) study.

20 Jul 2010

ViroStatics to present VS411 Phase II dose-ranging trial data at International AIDS Conference in Vienna

ViroStatics, a US/Italian biopharmaceutical company developing innovative immunotherapies for HIV/AIDS and other chronic diseases, is releasing Phase II data from a randomized, dose-ranging trial of VS411, the Company's novel combination product for treating HIV/AIDS, during the XVII International AIDS Conference this week in Vienna, Austria.

19 Jul 2010

ICON opens purpose-built clinical pharmacology unit within CMFT campus

ICON plc,, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the official opening of a purpose-built clinical pharmacology unit within the Central Manchester University Hospitals Foundation Trust (CMFT) campus in Manchester, UK. Initial studies in the unit utilising translational medicine methodologies to expedite drug development projects began in June, and already 110 volunteers have participated in studies there.

17 Jul 2010

NEOP receives stockholder approval to increase company shares to 205 milliion

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, announced at its 2010 Annual Meeting of Stockholders that it received the approval of its stockholders to increase the number of authorized shares of the Company from 155 million to 205 million. In addition, stockholders re-elected Neoprobe President and CEO David C. Bupp, and elected for the first time, Brendan A. Ford and Eric K. Rowinsky, M.D. as Directors of the Company for terms ending at the 2013 Annual Meeting. Stockholders also approved the appointment of BDO Seidman, LLP to act as the Company's independent registered public accounting firm for 2010.

17 Jul 2010

Impact of circadian dysregulation on mental, physical health

Circadian (daily) rhythms are found in all functions - e.g. performance, mood, endocrine rhythms, behaviour, sleep timing. The biological clocks that control circadian rhythms are based on a genetic programme of interacting molecules in cells throughout the body, coordinated by a ´master clock´ in the brain and synchronised by external cues, mainly light.

16 Jul 2010

An overview of AAPM annual meeting

AAPM is the premier organization in medical physics, a broadly-based scientific and professional discipline encompassing physics principles and applications in medicine and biology. Its membership includes medical physicists who specialize in research that develops cutting-edge technologies and board-certified clinical medical physicists who apply these technologies in community hospitals, clinics, and academic medical centers.

16 Jul 2010

VIVUS disappointed with FDA Advisory Committee's vote on QNEXA for obesity treatment

VIVUS, Inc. today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted against the following question: "Based on the current available data, do you believe the overall benefit-risk assessment of PHEN/TPM (QNEXA) is favorable to support its approval for the treatment of obesity in individuals with a BMI > 30 kg/m2 or > 27 kg/m2 with weight-related co-morbidities?" The three co-morbidities included hypertension, diabetes and dyslipidemia.

16 Jul 2010

JDD publishes long-term efficacy and tolerability study of PyratineXR Moisturizing Lotion

The June 2010 issue of Journal of Drugs in Dermatology (JDD), a full-color, peer-reviewed publication serving the dermatology community, features a study on the long-term efficacy and tolerability of the active ingredient in PyratineXR™.

16 Jul 2010

Aeras, CHC collaborate in Cambodian tuberculosis prevalence study

The Aeras Global TB Vaccine Foundation and the Cambodian Health Committee today announce the initiation of a study of tuberculosis prevalence in Svay Rieng Province, Cambodia, beginning this month. This is the first study conducted in partnership by the two non-profit research organizations and the first Aeras-sponsored study to be conducted in Cambodia.

16 Jul 2010

Columbia scientists discover new way to alleviate chronic pain

Columbia scientists working to combat injury-related depression, substance abuse and suicide due to unremitting, persistent pain may have discovered a new way of treating that pain: a powerful analgesic dubbed N60 that leads to neither tolerance nor addiction.

16 Jul 2010

Noscira presents results of Nypta Phase IIa clinical trial for AD at ICAD 2010

Noscira, the Grupo Zeltia (ZEL.MC) subsidiary specialized in researching and developing drugs for treating neurodegenerative diseases, presented the results of a Phase IIa clinical trial of Nypta(R) (Tideglusib) on Alzheimer's disease (AD) at the International Conference on Alzheimer's Disease (ICAD), held in Honolulu (Hawaii) from July 10-15, 2010.

16 Jul 2010